AC
SGMO

Armistice Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Armistice Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.97M Buy
+40,400,067
New +$16.1M 0.18% 91
2024
Q3 		– Sell
-14,060,000
Closed -$5.04M – 312
2024
Q2 		$5.04M Sell
14,060,000
-2,898,477
-17% -$1.57M 0.06% 116
2024
Q1 		$11.4M Buy
+16,958,477
New +$12.3M 0.15% 93

Other funds holding SGMO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Armistice Capital's SGMO Position: Q1 2026 in Review

Armistice Capital opened a new position in SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026: 40,400,067 shares worth $9.97M. The stake represents 0.18% of the portfolio and ranks #91 among its holdings. This is a return to the name: Armistice Capital previously reported a position in SGMO as recently as Q2 2024.

Armistice Capital first reported a position in SGMO in Q1 2024 and has held it in 3 quarters since. The position peaked at $11.4M in Q1 2024. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Armistice Capital held 40,400,067 shares of SANGAMO THERAPEUTICS INC worth $9.97M as of Q1 2026.
  • SANGAMO THERAPEUTICS INC was a new Armistice Capital position in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up 0.18% of Armistice Capital's portfolio in Q1 2026, its #91 holding.
  • Armistice Capital first reported a position in SANGAMO THERAPEUTICS INC in Q1 2024 and has held it in 3 quarters since.
  • Armistice Capital's SANGAMO THERAPEUTICS INC position peaked at $11.4M in Q1 2024.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.